---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014223"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:02:57.859187+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q2 2022 revenue $18.5M; cash $580.8M; FT516 RMAT meeting set

## Summary
- Q2 2022 collaboration revenue $18.5M from Janssen and ONO; R&D expense $81.3M, G&A $20.4M; cash $580.8M at June 30.
- FT516 RMAT meeting with FDA scheduled for 3Q22 to discuss registrational pathways for relapsed/refractory aggressive B-cell lymphoma.
- First patient dosed with FT536 CAR MICA/B NK cell product candidate for advanced solid tumors; multi-dose enrollment ongoing.
- Janssen exercised commercial option for first iPSC-derived CAR NK collaboration program; first IND planned 2H22.
- Expanded ONO collaboration: second solid tumor antigen program added, both CAR NK and CAR T candidates in development.

## SEC filing metadata
- accession: 0000950170-22-014223
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017022014223/0000950170-22-014223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017022014223/fate-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014223
- JSON: https://secwatch.observer/filing/0000950170-22-014223.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.